State of Iowa IBPE_News, Events and Press Releases Update

Having trouble viewing this email? View it as a Web page.
Iowa Board of Pharmacy
 
You are subscribed to IBPE_News, Events and Press Releases for Iowa Board of Pharmacy. There are new Press Releases available for your review.
 
FDA-Approved Cannabidiol Products Scheduled CV
10/04/2018 01:02 PM CDT

Date: 
Thursday, October 4, 2018

The Iowa Board of Pharmacy has filed emergency rule making to schedule as a Schedule V controlled substance any FDA-approved drugs that contain cannabidiol (CBD) derived from cannabis and no more than 0.1 percent tetrahydrocannabinols. This emergency scheduling follows the final order published September 28, 2018 in the Federal Register with identical scheduling action by DEA. DEA scheduling of these products follows the recent Food and Drug Administration approval of Epidiolex®. The Board’s rule making, effective October 3, 2018, temporarily places this drug into Schedule V of the Iowa Uniform Controlled Substances Act (CSA). As required by Iowa Code, the Board has also filed through the routine rule making process a Notice of Intended action for the same scheduling action for the purpose of seeking public input.
 
Our Board is comprised of five pharmacist members and two public members. The Board is responsible for regulating the practice of pharmacy and the legal distribution and dispensing of prescription drugs and precursor substances throughout Iowa. The responsibilities include, but are not limited to, licensing, renewal, and discipline of pharmacists, pharmacies, drug wholesalers, pharmacist-interns, pharmacy technicians, and persons or businesses involved in the distribution of controlled substances in Iowa, and continuing education for pharmacists.